Publications by authors named "Emily Jen"

Claim this Profile
A
Advancing drug development in myelodysplastic syndromes.
Alain Mina, Kathy L McGraw, Lea Cunningham, Nina Kim, Emily Y Jen

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.
Andrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, Rachel Ershler, Emily Y Jen

Clin Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Drug Development in Myelodysplastic Syndromes.
Mikkael A Sekeres, Nina Kim, Amy E DeZern, Kelly J Norsworthy, Jacqueline S Garcia, Emily Y Jen

Clin Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.
Emily Y Jen, Xin Wang, Meng Li, Hongshan Li, Shwu-Luan Lee

Clin Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Emily Y Jen, Xin Gao, Liang Li, Luning Zhuang, Natalie E Simpson

Clin Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
Emily Y Jen, Qing Xu, Aaron Schetter, Donna Przepiorka, Yuan Li Shen

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Emily Y Jen, Chia-Wen Ko, Jee Eun Lee, Pedro L Del Valle, Antonina Aydanian

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.
Emily Y Jen, Nancy J Poindexter, Elizabeth S Farnsworth, Elizabeth A Grimm

Melanoma Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.
Nancy J Poindexter, Ryan R Williams, Garth Powis, Emily Jen, Abigail S Caudle

Exp Dermatol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes.
Rebecca L H Bigelow, Emily Y Jen, Maryse Delehedde, Nikhil S Chari, Timothy J McDonnell

J Invest Dermatol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis